Cargando…
SAT438 Nivolumab Induced Endocrinopathies- Outcomes And Learning
Disclosure: K. Kethireddi: None. S. Jhetam: None. S.B. Parthasarathy: None. Background: Nivolumab is an anti PD-1 mAB (Programmed Cell Death protein) used in the treatment of melanoma, renal, head & neck and other cancers. Use of Nivolumab either as a single therapy or in combination with other...
Autores principales: | Kethireddi, Keerthi Madhurya, Jhetam, Suhail, Parthasarathy, Sathish Babu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555001/ http://dx.doi.org/10.1210/jendso/bvad114.1068 |
Ejemplares similares
-
SAT443 Prevalence Of Immune Checkpoint Inhibitor-related Endocrinopathies In Patients With Cancers
por: Pittampalli, Shanti, et al.
Publicado: (2023) -
PSUN160 Transfusion Related Endocrinopathies and Thalassemia (TREAT) Study
por: Erkin-Cakmak, Ayca, et al.
Publicado: (2022) -
SAT437 Immunotherapy Induced Pituitary Apoplexy
por: Uddin, Ashraf, et al.
Publicado: (2023) -
SAT440 DRESS/DHIS-associated Thyroiditis And Hypophysitis
por: Ranasinghe, Indika R, et al.
Publicado: (2023) -
SAT640 Maternal Preconception Exposure Leads To The Propagation Of Disease
por: Davis, Daniel Dewitt, et al.
Publicado: (2023)